Ensysce Biosciences Inc Ordinary Shares ENSC 深 滬
等待開盤 10-01 09:30:00 美东时间
2.37
+0.030
+1.28%
華盛通- 最 高2.43
- 今 開2.37
- 成交量 18.31万股
- 最 低 2.22
- 昨 收 2.34
- 總市值 703.51万
- 52周最高 14.67
- 市盈率 靜 --
- 換手率 6.17%
- 52周最低 1.62
- 委 比 0.00%
- 總股本 296.84万
- 歷史最高 61632.00
- 量 比 1.26
- 振 幅 8.97%
- 歷史最低 1.62
- 每 手 1
- 風險率 2.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ensysce Biosciences Advances Opioid Therapy Innovations
Ensysce Biosciences, Inc. ( ($ENSC) ) has released its Q2 earnings. Here is a b...
08-14 12:27
Ensysce Biosciences Q2 EPS $(0.79) Beats $(1.18) Estimate, Sales $1.371M Beat $650.000K Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.18) by 33.05 percent. This is a 76.06 percent increase over losses of $(3.30) per share
08-14 04:20
Ensysce Biosciences shares are trading higher after the company announced it received FDA feedback for PF614-MPAR.
Ensysce Biosciences shares are trading higher after the company announced it re...
07-31 21:06
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) stock rose 62.6% to $8.78 during Thurs...
07-31 20:08
Ensysce Biosciences Launches Phase 3 Trial For Abuse-Resistant Painkiller PF614, Selects Rho, Inc. As Clinical Partner
~ FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage
07-16 20:05
Ensysce Biosciences Says It Fully Enrolled Part 2 Of Critical Three-Part PF614-MPAR-102 Clinical Study To Study Effect Of Food On MPAR Technology
~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Development Program ~SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce Biosciences,
06-24 20:11
Ensysce Biosciences Secures $5.3M In Continued NIDA Support To Advance Opioid Overdose Protection
~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~
06-04 20:13
Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(3.02) by 53.97 percent. This is a 83.07 percent increase over losses of $(8.21) per share
05-14 04:39
Ensysce Biosciences announces exercise of warrants for $2.2M gross proceeds
Ensysce Biosciences (NASDAQ:ENSC) has entered a definitive agreements for the immediate exercise of certain outstanding warrants for gross proceeds of around $2.2M. ENSC -21.52% after hours to $2.88. ...
04-24 05:13
Ensysce Biosciences Advances in Opioid Innovation
Ensysce Biosciences, Inc. ( ($ENSC) ) has released its Q4 earnings. Here is a b...
03-20 11:57
